Investor Presentaiton

47 CELLECTRAⓇ Platform CELLECTRA-5PSP Intramuscular EP CELLECTRA-3P Intradermal EP CELLECTRA-3P technology in a hand-held portable device CELLECTRAⓇ 2000 EP Technology - Track record of success in the clinic . . . • > 2,000 human subjects and >7,000 doses CELLECTRA® 5PSP device developed to support Phase 3 and commercial launch Phase 2 efficacy data combining DNA vaccine and EP Global - Regulatory approval for studies in 6 continents (including Central & Sub-Saharan Africa); both devices CE marked in Europe INOVIO POWERING DNA MEDICINES

View entire presentation